

10815589

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:49:15 ON 20 JAN 2007

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 18:49:29 ON 20 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

DICTIONARY FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:



<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10815589.str

SAEED

10815589



chain nodes :

18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

chain bonds :

6-7 10-13 14-18

ring bonds :

1-2 1-5 1-6 2-3 2-6 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-17  
14-15 15-16 16-17

exact/norm bonds :

1-2 1-5 1-6 2-3 2-6 3-4 4-5 6-7 10-13 13-14 13-17 14-15 14-18 15-16  
16-17

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 7 : 13 :

G1:O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS

L1 STRUCTURE UPLOADED


SAEED

10815589

=> D

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 18:49:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 23 TO ITERATE

100.0% PROCESSED 23 ITERATIONS

12 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 173 TO 747

PROJECTED ANSWERS: 33 TO 447

L2 12 SEA SSS SAM L1

=> S L1 FULL

FULL SEARCH INITIATED 18:49:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 513 TO ITERATE

100.0% PROCESSED 513 ITERATIONS

221 ANSWERS

SEARCH TIME: 00.00.01

L3 221 SEA SSS FUL L1

=> FILE CPLUS

'CPLUS' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 18:50:14 ON 20 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

SAEED

10815589

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jan 2007 VOL 146 ISS 5  
FILE LAST UPDATED: 19 Jan 2007 (20070119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L3

L4                    5 L3

=> D IBIB ABS HITSTR TOT

10815589

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2006:87075 CAPLUS

DOCUMENT NUMBER: 144:343035

TITLE:

Conformational constraint in oxazolidinone antibacterials. Part 2: Synthesis and structure-activity studies of oxa-, aza-, and thiabicyclo[3.1.0]hexylphenyl oxazolidinones

Renslo, Adam R.; Gao, Hongwu; Jaishankar, Priyadarshini; Venkatachalam, Revathy; Gomez,

AUTHOR(S):

Marcela;

Blais, Johannes; Huband, Michael; Vara Prasad, J. V. M.; Gordeev, Mikhail P.

Corporate Source: Pfizer Global Research and Development, Fremont, CA, 94555, USA

SOURCE:

Bioorganic & Medicinal Chemistry Letters (2006), 16(5), 1126-1129

CODEN: BMCLE8; ISSN: 0960-894X

Elsevier B.V.

PUBLISHER:


DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GI


CASREACT 144:343035



AB Nonracemic oxa-, aza-, and dioxothiabicyclohexylphenyl oxazolidinylmethylcarboxamides I [R, R1 = H, F; R2 = Me, Et, HOCH2, NCCH2, MeCF2, cyclopropyl, cyclobutyl; R3 = HOCH2CO, OHC, NC, H2NCO, H2NCH2CO, AcNHCH2CO, NCCH2CO, MeO2C, F2CHCO, HOCH2CO, NCCH2CH2, FCH2CH2, HOCH2CH2, H2NC(:NH), H2NC(:NCN), MeNHC(:NCN), 5-tetrazolyl, 2-Me-5-tetrazolyl, 3-Me-5-tetrazolyl; X = SO2, O, NR3] are prepared as antibacterial agents. The structure-activity relationships of I [R, R1 = H, F; R2 = Me, Et, HOCH2, NCCH2, MeCF2, cyclopropyl, cyclobutyl; R3 = HOCH2CO, OHC, NC, H2NCO, H2NCH2CO, AcNHCH2CO, NCCH2CO, MeO2C, F2CHCO, HOCH2CO, NCCH2CH2, FCH2CH2, HOCH2CH2, H2NC(:NH), H2NC(:NCN), MeNHC(:NCN), 5-tetrazolyl, 2-Me-5-tetrazolyl, 3-Me-5-tetrazolyl; X = SO2, O, NR3] against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis, Haemophilus influenzae, and Moraxella catarrhalis are determined in vitro. I (R, R1 = H, F; R2 = Me; R3 = HOCH2CO; X = SO2, R3N) are effective in vitro against Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

Absolute stereochemistry.



IT 777088-23-0P 777088-24-1P 777088-25-2P  
777088-27-4P 777088-28-5P 777088-30-9P  
777088-32-1P 777088-33-2P 777088-34-3P  
777088-35-4P 777088-36-5P 777088-39-8P  
777088-51-4P 777088-53-6P 777088-54-7P  
777088-55-8P 777088-63-8P 777088-64-9P  
777088-65-0P 777088-66-1P 777088-69-4P  
777088-71-8P 777088-73-0P 777088-75-2P  
777088-77-4P 777088-78-5P 777088-80-9P  
777088-87-6P 777088-88-7P 777088-90-1P  
777088-91-2P 777090-05-8P 777090-07-0P  
881012-69-7P 881012-70-0P 881012-71-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of nonracemic oxa-, aza-, and dioxothiabicyclo[3.1.0]hexylphenyl oxazolidinylmethyl carboxamides as antibacterial agents and their antibacterial structure-activity relationships)  
RN 777088-23-0 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-24-1 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

SAEED

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)  
faecalis, Haemophilus influenzae, and Moraxella catarrhalis and are effective as oral agents in an in vivo mouse septicemia model.

IT 777088-62-7P 777089-37-9P 777089-75-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation of nonracemic oxa-, aza-, and dioxothiabicyclo[3.1.0]hexylphenyl oxazolidinylmethyl carboxamides as antibacterial agents and their antibacterial structure-activity relationships)

RN 777088-62-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(1H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 777089-37-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[(1a,5a,6a)-4-[(1R,5S)-3-(1H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-75-5 CAPLUS

CN Acetamide, [[[(5S)-3-[4-[(1a,5a,6a)-3-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


Absolute stereochemistry.



RN 777088-25-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-27-4 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-28-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-formyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

10815589


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
INDEX NAME

Absolute stereochemistry.



RN 777088-30-9 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-5-oxazolidinyl]-2-fluorophenyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-32-1 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
RN 777088-35-4 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 777088-36-5 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 777088-39-8 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-33-2 CAPLUS  
CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 777088-34-3 CAPLUS  
CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-51-4 CAPLUS  
CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(2-hydroxy-2-methyl-1-oxopropyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-53-6 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-(difluoroacetyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-54-7 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-(aminoacetyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

10815589


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-55-8 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-[(acetylamino)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-63-8 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(1-methyl-1H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-66-1 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-(2-cyanoethyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-69-4 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-71-8 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-64-9 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-65-0 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(2-hydroxyethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-73-0 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-75-2 CAPLUS  
CN Cyclobutanecarboxamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-77-4 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-

10815589


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-78-5 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-80-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-90-1 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-[(cyanoamino)(methylimino)methyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-91-2 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-[(cyanoamino)iminomethyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777090-05-8 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-87-6 CAPLUS  
CN Acetamide, 2-cyano-N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-88-7 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-(aminoiminomethyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777090-07-0 CAPLUS  
CN Acetamide, 2-cyano-N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881012-69-7 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10815589

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 881012-70-0 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-(cyanoacetyl)-3-methyl-2H-tetrazol-5-yl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 881012-71-1 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(2-methyl-2H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-38-0 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(phenylmethoxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-52-8 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-(phenylmethoxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-56-3 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-(phenylmethoxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



SABED


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

IT 777088-21-8P 777089-36-8P 777089-38-0P  
 777089-52-8P 777089-56-2P 777089-65-3P  
 777089-68-6P 777089-77-7P 777089-78-8P  
 777089-79-9P 777089-80-2P 777089-81-3P  
 777089-90-4P 777089-91-5P 777089-93-7P  
 777089-94-8P 777090-04-7P 777090-06-9P  
 777090-09-2P 881012-67-5P 881012-68-6P  
 881012-72-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of nonracemic oxa-, aza-, and dioxothiazabicyclo[3.1.0]hexylphenylloxazolidinylmethyl carboxamides as antibacterial agents and their antibacterial structure-activity relationships)


RN 777088-21-8 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-36-8 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-65-3 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-68-6 CAPLUS  
 CN Acetamide, N-[(5S)-2-oxo-3-[4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-77-7 CAPLUS  
 CN Carbamic acid, [(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-78-8 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-79-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-90-4 CAPLUS  
CN Carbamic acid, [[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-91-5 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-93-7 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-80-2 CAPLUS  
CN Propanamide, 2,2-difluoro-N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-81-3 CAPLUS  
CN Cyclobutanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-94-8 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777090-04-7 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAEED

10815589


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 777090-06-9 CAPLUS  
 CN Acetamide, 2-cyano-N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777090-09-2 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881012-67-5 CAPLUS  
 CN Acetamide, N-[[[(5S)-2-oxo-3-[4-[(1a,5a,6a)-3-[(phenylmethoxy)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 881012-68-6 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 881012-72-2 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2005:441722 CAPLUS  
 DOCUMENT NUMBER: 143:133245  
 TITLE: Synthesis of Aza-, Oxa-, and Thiabicyclo[3.1.0]hexane Heterocycles from a Common Synthetic Intermediate  
 Renslo, Adam R.; Gao, Hongwu; Jaishanker, Priyadarshini; Venkatachalam, Revathy; Gordeev, Mikhail F.  
 AUTHOR(S): Department of Medicinal Chemistry, Vicuron Pharmaceuticals, Fremont, CA, 94555, USA  
 ORGANIC LETTERS (2005), 7(13), 2627-2630  
 CODEN: ORLEP7; ISSN: 1523-7060  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 143:133245  
 AB An efficient and stereospecific approach to the synthesis of structurally constrained aza-, oxa-, and thiabicyclo[3.1.0]hexane heterocycles has been achieved through application of the intramol. cyclopropanation reaction of diazoacetates. The various constrained heterocycles (X = N, O, or S) are conveniently prepared from a common diol intermediate accessible from readily available cinnamyl alcs. Application of the methodol. to the synthesis of conformationally constrained oxazolidinone antibacterials is also discussed.  
 IT 777089-36-8 777089-65-3  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of aza-, oxa-, and thiabicyclo[3.1.0]hexanes from a common diol intermediate)  
 RN 777089-36-8 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-65-3 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Applicat

10815589

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




IT 777088-21-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of aza-, oxa-, and thiabicyclo[3.1.0]hexanes from a common diol intermediate)

RN 777088-21-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 777088-23-0P 777089-37-9P 858367-40-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of aza-, oxa-, and thiabicyclo[3.1.0]hexanes from a common diol intermediate)


RN 777088-23-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS  
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-37-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 858367-40-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:55213 CAPLUS  
DOCUMENT NUMBER: 142:134582  
TITLE: Preparation of oxazolidinone antibacterials  
INVENTOR(S): Hammond, Milton L.; Fukuda, Yasumichi  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Kyorin Pharmaceutical Co., Ltd.  
SOURCE: PCT Int. Appl., 58 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005399	A1	20050120	WO 2004-US20736	20040629
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004256084	A1	20050120	AU 2004-256084	20040629
CA 2529292	A1	20050120	CA 2004-2529292	20040629
EP 1656357	A1	20060517	EP 2004-777198	20040629
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
CN 1816534	A	20060809	CN 2004-80018878	20040629
US 2006247286	A1	20061102	US 2006-559845	20060505
PRIORITY APPLN. INFO.:			US 2003-483905P	P 20030702
			US 2004-546947P	P 20040224
			US 2004-553963P	P 20040318
			WO 2004-US20736	W 20040629

OTHER SOURCE(S): MARPAT 142:134582  
G1



SAAED

10815589

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 AB Title Comps. [1; R1 = H, NRSR6, CR7R8R9, COR13, (substituted)  
 heterocyclyl, etc.; A = NR, O, S, SO, S02; Ar = (substituted) aryl,  
 heteroaryl, heterocyclyl; R3 = NR13(C:R2)R12, NR13SO2R14, (substituted)  
 heteroaryl, etc.; n = 0, 1; Rx = H, alkyl; R5, R6 = H, (substituted)  
 alkyl, acyl, heterocyclyl, etc.; R5R6, R7R8 = atoms to form a 3-7  
 membered

heterocyclic ring; R7 = H, halo, cyano, CHO, OH, alkyl, alkoxy, alkenyl,  
 etc.; R8, R9 = H, cyano, (substituted) alkyl, Ph; R13 = H, alkyl, aryl,  
 NRSR6, cyano, OH, alkylcarbonyl, CO2H, acyl, (substituted) (heterocyclic)  
 ring, etc.; R14 = amino, alkyl, haloalkyl, (substituted) heterocyclyl,  
 Ph;

X2 = O, S, NH, NSO2R14], were prepared. Thus, 1-benzoyloxycarbonylamino-4-  
 [(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]benzene in  
 THP at -78° was treated with BuLi and then with (R)-glycidyl  
 butyrate followed by stirring for 2 h gave 5(R)-3-[(4-  
 [(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]-5-  
 hydroxymethyl-oxazolidin-2-one. The latter was stirred 15 min. with Et3N  
 and MeSO2Cl in CH2Cl2 at 0° to give a residue which was stirred at  
 70° with NaN3 in DMF to give 5(R)-azidomethyl-3-[(4-  
 [(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-  
 yl)]phenyl]oxazolidin-2-one. The latter was hydrogenated in THP/MeOH


over Lindlar catalyst to give 5(R)-aminomethyl-3-[(4-  
 [(1a,5a,6b)-(6-cyanobicyclo[3.1.0]hexan-6-  
 yl)]phenyl]oxazolidin-2-one. This was stirred with Et3N and Ac2O in THP  
 at 0°-room temperature to give N-[(5S)-3-[(4-[(1a,5a,6b)-  
 (6-cyanobicyclo[3.1.0]hexan-6-yl)]phenyl]oxazolidin-5-ylmethyl]acetamide.  
 The latter showed a min. inhibitory concentration of 0.25 µg/mL against  
 Staphylococcus Aureus Smith.

IT 827014-73-3P 827014-78-8P 827015-38-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(claimed compound; preparation of oxazolidinone antibacterials)

RN 827014-73-3 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[4-[(5S)-5-  
 [(acetylaminomethyl)-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-  
 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(claimed compd.; prepn. of oxazolidinone antibacterials)

RN 827014-74-4 CAPLUS

CN Acetamide, N-[(5S)-3-[(4-[(1a,5a,6b)-6-cyano-3-  
 azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 827014-75-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[4-[(5R)-2-oxo-5-  
 (1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl  
 ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-76-6 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-(1H-1,2,3-  
 triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1a,5a,6b)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827014-78-8 CAPLUS

CN Acetamide, N-[(5S)-3-[(4-[(1a,5a,6b)-6-cyano-3-  
 (hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-  
 oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827015-38-3 CAPLUS

CN Acetamide, N-[(5S)-3-[(4-[(1a,5a,6b)-6-cyano-3-  
 azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-,  
 monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HCl

IT 827014-74-4P 827014-75-5P 827014-76-6P  
 827014-77-7P 827014-78-8P 827014-80-2P  
 827014-81-3P 827014-82-4P 827014-83-5P  
 827014-84-6P 827014-85-7P 827014-86-8P  
 827014-87-9P 827014-88-0P 827014-89-1P  
 827014-90-4P 827014-91-5P 827014-92-6P  
 827014-94-8P 827014-95-9P 827014-97-1P  
 827014-99-3P 827015-01-0P 827015-03-2P  
 827015-05-4P 827015-07-6P 827015-09-8P  
 827015-11-2P 827015-45-2P 827015-47-4P  
 827015-49-6P 827015-51-0P 827015-53-2P


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827014-77-7 CAPLUS

CN Acetamide, N-[(5S)-3-[(4-[(1a,5a,6b)-3-  
 [(acetyloxyacetyl)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-  
 oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827014-79-9 CAPLUS

CN Acetamide, N-[(5S)-3-[(4-[(1a,5a,6b)-6-cyano-3-  
 (methylsulfonyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-  
 oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-80-2 CAPLUS

CN Acetamide, N-[(5S)-3-[(4-[(1a,5a,6b)-6-cyano-3-methyl-3-  
 azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)


(CA INDEX NAME)

SAEED

10815589


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 827014-81-3 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-3,6-dicyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 827014-82-4 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-6-cyano-3-(cyanomethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[4-[(5R)-5-[[[(1,1-dimethylethoxy)carbonyl]-3-isoxazolyamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-86-8 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5S)-5-[(3-isoxazolyamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1a,5a,6β)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827014-87-9 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-6-cyano-3-(5-cyano-2-pyridinyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827014-83-5 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827014-84-6 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-5-[(3-isoxazolyloxy)methyl]-2-oxo-3-oxazolidinyl]phenyl]-, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827014-85-7 CAPLUS

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827014-88-0 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-6-cyano-3-(2-pyridinyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-89-1 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-3-acetyl-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827014-90-4 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-6-cyano-3-(2-pyrimidinyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

10815589


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 827014-91-5 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[[[(1a,5a,6β)-6-cyano-3-[(4-pyridinylmethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827014-92-6 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[[[(1a,5a,6β)-6-cyano-3-[(1-cyanoamino)ethyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 827014-97-1 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[[[(1a,5a,6β)-6-cyano-3-[(cyanoamino)iminomethyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827014-99-3 CAPLUS  
CN Carbamic acid, [[[(1a,5a,6β)-6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-3-azabicyclo[3.1.0]hex-3-yl] [[[(1,1-dimethylethoxy)carbonyl]amino)methylene]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827015-01-0 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[[[(1a,5a,6β)-3-(aminoiminomethyl)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 827014-94-8 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-, methyl ester, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827014-95-9 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboximidothioic acid, 6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-N,6-dicyano-, methyl ester, (1a,5a,6β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 827015-03-2 CAPLUS  
CN Carbamic acid, [2-[[[(1a,5a,6β)-6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 827015-03-2 CAPLUS  
CN Carbamic acid, [2-[[[(1a,5a,6β)-6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827015-05-4 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[[[(1a,5a,6β)-3-(aminoacetyl)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 827015-07-6 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[[[(1a,5a,6β)-6-cyano-3-[(methylsulfonyl)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

SAEED

10815589


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 827015-09-8 CAPLUS  
CN Phosphoric acid, 2-[(1a,5a,6b)-6-[4-[(5S)-5-[[acetamido)methyl]-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-3-azabicyclo[3.1.0]hex-3-yl]-2-oxoethyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 827015-11-2 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6b)-6-cyano-3-[[phosphonoxy]acetyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 827015-45-2 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-2-oxo-5-[(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 827015-47-4 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5R)-5-[(3-oxazolidinyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 827015-49-6 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-6-carbonitrile, 6-[4-[(5S)-5-[(3-oxazolidinyl)oxy]methyl]-2-oxo-3-oxazolidinyl]phenyl]-, monohydrochloride, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 827015-51-0 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6b)-3-(aminoiminomethyl)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 827015-53-2 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6b)-3-(aminoacetyl)-6-cyano-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 827015-36-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of oxazolidinone antibacterials)  
RN 827015-36-1 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[4-[(5R)-5-(azidomethyl)-2-oxo-3-oxazolidinyl]phenyl]-6-cyano-, 1,1-dimethylethyl ester, (1a,5a,6b)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10815589

L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



IT 827015-17-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxazolidinone antibacterials)

RN 827015-17-8 CAPLUS

CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-cyano-6-[(5R)-5-(hydroxymethyl)-2-oxo-3-oxazolidinyl]phenyl]-, 1,1-dimethylethyl ester, (1 $\alpha$ ,5 $\alpha$ ,6 $\beta$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN

ACCESSION NUMBER: 2004:872795 CAPLUS

DOCUMENT NUMBER: 141:366217

TITLE: Preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivatives as antimicrobials

INVENTOR(S): Renalo, Adam Robert; Gordeev, Mikhail Fedor; Patel, Dinesh Vinooobhai; Gao, Hongwu; Josyula, Vara Prasad Venkata Nagendra

PATENT ASSIGNER(S): Pharmacia &amp; Upjohn Company, LLC, USA

SOURCE: PCT Int. Appl., 187 pp.

CODEN: FIKX2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2004089943	A1	20041021	WO 2004-1B1135	20040330
WO 2004089943	AS	20050929		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KE, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
CA 2521685	A1	20041021	CA 2004-2521685	20040330
EP 1615916	A1	20060118	EP 2004-724333	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, PL, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009217	A	20060328	BR 2004-9217	20040330
JP 2005522791	T	20061005	JP 2006-506470	20040330
US 2005192225	A1	20050901	US 2004-815589	20040401
PRIORITY APPL. INFO.:				US 2003-461134P P 20030409
				WO 2004-1B1135 W 20040330


OTHER SOURCE(S): MARPAT 141:366217

GI

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



I



II

AB Title compds. I [A = oxazolyl, isoxazolyl, etc.; n = 0-1; Y = SOO-2, O, amino; Z = formyl, thioformyl, acyl, etc.; W = CH<sub>2</sub>, CO, oximino, etc.; R<sub>1</sub> = H, OH, amino, etc.; R<sub>2</sub>-3 = H, F; R<sub>4</sub>-5 = H, Cl, F, Me, NH<sub>2</sub>, OH; R<sub>6</sub>-7 =

H, alkyl] are prepared. For example, II is prepared in 9 steps from 2-fluoro-4-nitrobenzaldehyde. II has MIC = 4  $\mu$ g/mL for *S. aureus* (UC9213). I are antibacterial agents.


IT 777088-74-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)

RN 777088-74-1 CAPLUS

CN Cyclobutanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 777088-21-8P 777088-22-9P 777088-23-0P  
777088-24-1P 777088-25-2P 777088-26-3P

SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

777088-27-4P 777088-28-5P 777088-29-6P

777088-30-9P 777088-31-0P 777088-32-1P

777088-33-2P 777088-34-3P 777088-35-4P

777088-36-5P 777088-37-6P 777088-38-8P

777088-40-1P 777088-41-2P 777088-42-3P

777088-43-4P 777088-44-5P 777088-45-6P

777088-46-7P 777088-47-8P 777088-48-9P

777088-49-0P 777088-50-3P 777088-51-4P

777088-52-5P 777088-53-6P 777088-54-7P

777088-55-8P 777088-56-9P 777088-57-0P

777088-58-1P 777088-59-2P 777088-60-5P

777088-61-6P 777088-62-7P 777088-63-8P

777088-64-9P 777088-65-0P 777088-66-1P

777088-67-2P 777088-68-3P 777088-69-4P

777088-70-7P 777088-71-8P 777088-72-9P

777088-73-0P 777088-75-2P 777088-76-3P

777088-77-4P 777088-78-5P 777088-79-6P

777088-80-9P 777088-81-0P 777088-82-1P

777088-83-2P 777088-84-3P 777088-85-4P

777088-86-5P 777088-87-6P 777088-88-7P

777088-89-8P 777088-90-1P 777088-91-2P

777088-92-3P 777088-93-4P 777088-94-5P

777088-95-6P 777088-96-7P 777088-97-8P

777088-98-9P 777088-99-0P 777089-00-6P

777089-01-7P 777089-02-8P 777089-03-9P

777089-04-0P 777089-05-1P 777089-06-2P

777089-07-3P 777089-08-4P 777089-09-5P

777089-10-6P 777089-11-9P 777089-13-1P

777089-14-2P 777089-15-3P 777089-16-4P

777089-17-5P 777089-18-6P 777089-19-7P

777089-20-0P 777089-21-1P 777089-22-2P

777089-23-3P 777089-24-4P 777090-10-5P

780766-67-8P 780766-68-9P 780766-69-0P

780766-70-3P 780766-71-4P 780766-72-5P

780766-73-6P 780766-74-7P 780766-75-8P

780766-76-9P 780766-77-0P 780766-78-1P

780766-79-2P 780766-80-5P 780766-81-6P

780766-82-7P 780766-83-8P 780766-84-9P

780766-85-0P 780766-86-1P 780766-87-2P

780766-88-3P 780766-89-4P 780766-90-7P

780766-91-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)


RN 777088-21-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-22-9 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 777088-23-0 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-24-1 CAPLUS

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-27-4 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxylic acid, 6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, methyl ester, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-28-5 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-formyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 777088-29-6 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-[(2S)-2,3-

SAEED


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 777088-25-2 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-26-3 CAPLUS  
CN Ethanethioamide, 2,2-difluoro-N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


dihydroxy-1-oxopropyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-30-9 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[4-[(5S)-5-[(acetylamino)methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-31-0 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[4-[(5S)-5-[(2,2-difluoro-1-thioxoethyl)amino]methyl]-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-32-1 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-33-2 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-36-5 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-37-6 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-39-8 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-34-3 CAPLUS  
 CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-35-4 CAPLUS  
 CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-40-1 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-41-2 CAPLUS  
 CN Propanamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAEED

10815589


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 RN 777088-42-3 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-formyl-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-43-4 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-oxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-44-5 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-oxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-N-methyl-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-47-8 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(methoxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-48-9 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(2S)-2,3-dihydroxy-1-oxopropyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-45-6 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, N-ethyl-6-[2-fluoro-4-[(5S)-2-oxo-5-[[[(1-oxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-46-7 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-49-0 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(cyclopropylcarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-50-3 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-[(1-hydroxycyclopropyl)carbonyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-51-4 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-3-(2-


SAEED

10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

hydroxy-2-methyl-1-oxopropyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-52-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-[(2R)-

3,3,3-trifluoro-2-hydroxy-1-oxopropyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-53-6 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-(difluoroacetyl)-

3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 777088-56-9 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(5-isoxazolylcarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-57-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(1H-pyrazol-3-ylcarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 777088-58-1 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(1H-imidazol-4-ylcarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-54-7 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-(aminoacetyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-55-8 CAPLUS

CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3-

[(acetylamino)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 777088-59-2 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(1H-pyrazol-4-ylcarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-60-5 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-[[[(2R)-tetrahydro-2-furanyl]carbonyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-61-6 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-(2-pyrimidinyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

SAEED


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-62-7 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(1H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-63-8 CAPLUS  
 CN Acetamide,  
 N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(1-methyl-1H-tetrazol-5-yl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-66-1 CAPLUS  
 CN Acetamide,  
 N-[[[(5S)-3-[4-[(1R,5S)-3-(2-cyanoethyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-67-2 CAPLUS  
 CN Acetamide,  
 N-[[[(5S)-3-[4-[(1R,5S)-3-(dimethylamino)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-68-3 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-64-9 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(2-fluoroethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-65-0 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-(2-hydroxyethyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-69-4 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-70-7 CAPLUS  
 CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-71-8 CAPLUS

SAEED

10815589


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
 CN Cyclopropanecarboxamide, N-[[[(5S)-3-[4-[[[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-72-9 CAPLUS  
 CN Propanamide, 2,2-difluoro-N-[[[(5S)-3-[3-fluoro-4-[[[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-73-0 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[4-[[[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-77-4 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[4-[[[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-78-5 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[4-[[[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2,2-difluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-75-2 CAPLUS  
 CN Cyclobutanecarboxamide, N-[[[(5S)-3-[4-[[[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-76-3 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-[[[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-79-6 CAPLUS  
 CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3,5-difluoro-4-[[[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-80-9 CAPLUS  
 CN Cyclopropanecarboxamide, N-[[[(5S)-3-[4-[[[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-81-0 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2,6-difluoro-4-[[[(5S)-2-oxo-5-[[[(1-oxopropyl)amino]methyl]-3-oxazolidinyl]phenyl]-, (1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-82-1 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 777088-83-2 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexane-3-carboxamide, 6-[2,6-difluoro-4-[(1R,5S)-2-oxo-5-oxazolidinylmethyl]-2-oxo-5-oxazolidinyl]phenyl]- (1R,5S)- (9CI)  
 (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-86-5 CAPLUS  
 CN Acetamide, 2-cyano-N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-87-6 CAPLUS  
 CN Acetamide, 2-cyano-N-[[[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777088-84-3 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-85-4 CAPLUS  
 CN Acetamide, 2-cyano-N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-88-7 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-(aminoiminomethyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-89-8 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-(aminoiminomethyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 777088-90-1 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-[(cyanoamino)(methylimino)methyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-91-2 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1R,5S)-3-[(cyanoamino)iminomethyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-92-3 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777088-96-7 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-97-8 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-93-4 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-94-5 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777088-95-6 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777088-98-9 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777088-99-0 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-00-6 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1R,5S)-3-[(1E)-1-(methylamino)-2-nitroethenyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-01-7 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 2-oxo-3-[4-((1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl)phenyl]-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-02-8 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 2-oxo-3-[3-fluoro-4-((1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-03-9 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-((1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-04-0 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3,5-difluoro-4-((1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-05-1 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3,5-difluoro-4-((1R,5S)-3-(hydroxyacetyl)-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-06-2 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-((1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-07-3 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-((1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-08-4 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3,5-difluoro-4-((1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-09-5 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3,5-difluoro-4-((1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl)phenyl]-N-methyl-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

SAEED


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-10-8 CAPLUS  
CN Propanamide, N-[[[5S]-3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 777089-11-9 CAPLUS  
CN Propanamide, N-[[[5S]-3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-15-3 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-16-4 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-17-5 CAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-13-1 CAPLUS  
CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-14-2 CAPLUS  
CN 2-Oxazolidinone, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-18-6 CAPLUS  
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-19-7 CAPLUS  
CN Acetamide, N-[[[5S]-3-[3-fluoro-4-[(1S,5R,6R)-2-oxo-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-20-0 CAPLUS  
CN Acetamide, N-[[[5S]-3-[3,5-difluoro-4-[(1S,5R,6R)-2-oxo-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

SAEED

10815589


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)

Absolute stereochemistry.



RN 777089-21-1 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-[(1S,5R,6R)-2-oxo-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-22-2 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[3,5-difluoro-4-[(1S,5R,6R)-2-oxo-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)



RN 777089-23-3 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2-fluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-24-4 CAPLUS  
 CN 3-Azabicyclo[3.1.0]hexan-2-one, 6-[2,6-difluoro-4-[(5R)-2-oxo-5-(1H-1,2,3-triazol-1-ylmethyl)-3-oxazolidinyl]phenyl]-, (1S,5R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)




RN 777090-10-5 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-[(2S)-2-hydroxy-1-oxopropyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-67-8 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-68-9 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

SAAED


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STM (Continued)

Absolute stereochemistry.




RN 780766-69-0 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-70-3 CAPLUS  
 CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6β)-3-[(2S)-2-hydroxy-1-oxopropyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-71-4 CAPLUS  
 CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)

10815589


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 780766-72-5 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 780766-73-6 CAPLUS  
CN Propanamide, 2,2-difluoro-N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 780766-76-9 CAPLUS  
CN Acetamide, 2-cyano-N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-77-0 CAPLUS  
CN Acetamide, 2-cyano-N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 780766-78-1 CAPLUS


SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 780766-74-7 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-75-8 CAPLUS  
CN Cyclopropanecarboxamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1R,3a,5S,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-79-2 CAPLUS  
CN Acetamide, N-[[[(5S)-3-[4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 780766-80-5 CAPLUS  
CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 780766-81-6 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[3-fluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 780766-82-7 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 780766-83-8 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 780766-84-9 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[3,5-difluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)-(9CI)  
(CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 780766-85-0 CAPLUS  
CN 5-Oxazolidinecarboxamide, 3-[4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-N-methyl-2-oxo-, (5R)-(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 780766-86-1 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[3,5-difluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 780766-87-2 CAPLUS  
CN Propanamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 780766-88-3 CAPLUS  
CN 2-Oxazolidinone, 3-[3-fluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 780766-89-4 CAPLUS  
CN 2-Oxazolidinone, 3-[3,5-difluoro-4-[(1a,5a,6β)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)-(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

SAEED

10815589


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 780766-90-7 CAPLUS

CN Cyclobutanecarboxamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 780766-91-8 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1R,3a,5S,6B)-3-oxido-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-38-0 CAPLUS

CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-39-1 CAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 777089-36-8P 777089-37-9P 777089-38-0P

777089-39-1P 777089-40-4P 777089-41-5P

777089-42-6P 777089-43-7P 777089-44-8P

777089-52-8P 777089-56-2P 777089-63-1P

777089-65-3P 777089-66-4P 777089-68-6P

777089-72-2P 777089-73-3P 777089-74-4P

777089-75-5P 777089-77-7P 777089-78-8P

777089-79-9P 777089-80-2P 777089-81-3P

777089-90-4P 777089-91-5P 777089-92-6P

777089-93-7P 777089-94-8P 777089-97-1P

777089-98-2P 777089-99-3P 777090-00-3P

777090-01-4P 777090-02-5P 777090-03-6P

777090-04-7P 777090-05-8P 777090-06-9P


777090-07-0P 777090-08-1P 777090-09-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of [3.1.0]bicyclohexylphenyloxazolidinone derivs. as antimicrobials)

RN 777089-36-8 CAPLUS


CN Acetamide, N-[[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-37-9 CAPLUS


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-40-4 CAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-41-5 CAPLUS

CN Carbamic acid, [[[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-4-(3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAAED

10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-42-6 CAPLUS  
CN 3-Azabicyclo[3.1.0]hexane, 6-[4-[(5S)-5-(aminomethyl)-2-oxo-3-oxazolidinyl]-2-fluorophenyl]-3-(hydroxyacetyl)-, (1a,5a,6a)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-43-7 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-44-8 CAPLUS  
CN Carbamic acid, [(5S)-3-[4-[(1a,5a,6a)-3-(aminocarbonyl)-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-63-1 CAPLUS  
CN Carbamic acid, [(5S)-3-[4-[(1a,5a,6a)-3-oxabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-65-3 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-66-4 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-[(acetyloxy)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-52-8 CAPLUS  
CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-56-2 CAPLUS  
CN Acetamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-[(phenylmethoxy)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777089-68-6 CAPLUS  
CN Acetamide, N-[(5S)-2-oxo-3-[4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-5-oxazolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-72-2 CAPLUS  
CN 5-Oxazolidinecarboxylic acid, 3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-, ethyl ester, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-73-3 CAPLUS  
CN Propanamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-[(4-


SAEED



10815589


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-74-4 CAPLUS  
CN Propanamide, N-[(5S)-3-[4-[(1a,5a,6a)-3-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]carbonyl]-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-75-5 CAPLUS  
CN Acetamide, [(5S)-3-[4-[(1a,5a,6a)-3-cyano-3-azabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-79-9 CAPLUS  
CN Cyclopropanecarboxamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-80-2 CAPLUS  
CN Propanamide, 2,2-difluoro-N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-81-3 CAPLUS


SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-77-7 CAPLUS  
CN Carbamic acid, [(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-78-8 CAPLUS  
CN Propanamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)  
CN Cyclobutanecarboxamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777089-90-4 CAPLUS  
CN Carbamic acid, [(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-91-5 CAPLUS  
CN Propanamide, N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-92-6 CAPLUS  
 CN Carbamic acid, N-[(1S)-3-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777089-93-7 CAPLUS  
 CN Propanamide, N-[(1S)-3-[(1a,5a,6a)-3,5-difluoro-4-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777089-98-2 CAPLUS  
 CN Propanamide, N-[(1S)-3-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-99-3 CAPLUS  
 CN Propanamide, N-[(1S)-3-[(1a,5a,6a)-3-azabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinylmethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




SAEED

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777089-94-8 CAPLUS  
 CN Carbamic acid, N-[(1S)-3-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777089-97-1 CAPLUS  
 CN Carbamic acid, N-[(1S)-3-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 777090-00-3 CAPLUS  
 CN Propanamide, N-[(1S)-3-[(1a,5a,6a)-3-[(acetyloxy)acetyl]-3-azabicyclo[3.1.0]hex-6-yl]-3,5-difluorophenyl]-2-oxo-5-oxazolidinylmethyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777090-01-4 CAPLUS  
 CN 2-Oxazolidinone, 5-(azidomethyl)-3-[(3,5-difluoro-4-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777090-02-5 CAPLUS  
 CN 2-Oxazolidinone, 5-(azidomethyl)-3-[(3,5-difluoro-4-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(hydroxymethyl)-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10815589

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777090-03-6 CAPLUS  
CN 2-Oxazolidinone, 3-[(3,5-difluoro-4-[(1a,5a,6a)-3-[(4-methoxyphenyl)methyl]-3-azabicyclo[3.1.0]hex-6-yl]phenyl]-5-(1H-1,2,3-triazol-1-ylmethyl)-, (5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777090-04-7 CAPLUS  
CN Acetamide, N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 777090-05-8 CAPLUS  
CN Acetamide, N-[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]-2-hydroxy-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 777090-06-9 CAPLUS  
CN Acetamide, 2-cyano-N-[(5S)-3-[3-fluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 777090-07-0 CAPLUS  
CN Acetamide, 2-cyano-N-[(5S)-3-[4-[(1a,5a,6a)-3,3-dioxido-3-thiabicyclo[3.1.0]hex-6-yl]-3-fluorophenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777090-08-1 CAPLUS  
CN 2-Oxazolidinone, 5-(aminomethyl)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-, (5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 777090-09-2 CAPLUS  
CN Acetamide, 2-cyano-N-[(5S)-3-[3,5-difluoro-4-[(1a,5a,6a)-3-thiabicyclo[3.1.0]hex-6-yl]phenyl]-2-oxo-5-oxazolidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

SAEED

10815589

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:609963 CAPLUS

DOCUMENT NUMBER: 141:140424

TITLE:

INVENTOR(S):

Prasad

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004147760	A1	20040729	US 2003-646440	20030822
US 7141588	B2	20061128		
US 2004044052	A1	20040304	US 2003-373286	20030224
US 6919329	B2	20050719		
US 2007015801	A1	20070118	US 2006-524754	20060921
			US 2002-359495P	P 20020225
PRIORITY APPLN. INFO.:			US 2003-373286	A2 20030224
			US 2003-646440	A3 20030822


OTHER SOURCE(S):

GI


MARPAT 141:140424




I



II




III



IV


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)




RN 726169-61-5 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[4-(3-cyano-3-azabicyclo[3.1.0]hex-6-yl)-3-fluorophenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 726169-62-6 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-(2-oxo-3-oxabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 726169-63-7 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-(2-oxo-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)

AB Title compds. of formula I, II, and III (wherein B = (un)substituted cycloalkyl, cycloalkenyl, aryl, or heterocyclyl; C = (hetero)aryl (un)substituted with 1-3 R2; or BC = (un)substituted bicyclic heterocycle;

R1 = H, OH, cycloalkyl, NH2, or (un)substituted alkyl, alkoxy, or alkenyl;

R2 = independently H, NH2, NO2, CN, halo, or (un)substituted alkyl; with provisos; and pharmaceutically acceptable salts thereof] were prepared as antibacterial agents. Examples include syntheses and biol. data for 91 compds. For instance, benzyl 3-fluoro-4-(4-morpholinyl)phenylcarbamate was stirred with BuLi in THF at -78° for 30 min. Cycloaddn. with potassium (2R)-glycidate gave the 2-oxo-5-oxazolidinonecarboxylic acid, which was amidated using oxalyl chloride and ammonium to afford (R)-(-)-IV. Compds. of the invention inhibited growth of Staphylococcus aureus with MIC values ranging from 0.5 µg/mL to 16 µg/mL. Thus, I, II, and III and their pharmaceutical compns. are useful for the treatment of microbial infections.

IT 726169-59-1P 726169-60-4P 726169-61-5P

726169-62-6P 726169-63-7P 726169-64-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 3-aryl-2-oxo-5-oxazolidinonecarboxamides and analogs as antibacterial agents)

RN 726169-59-1 CAPLUS

CN 5-Oxazolidinonecarboxamide,

3-[3-fluoro-4-(3-hydroxy-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 726169-60-4 CAPLUS


CN 5-Oxazolidinonecarboxamide,

3-[3-fluoro-4-(3-methoxy-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

(Continued)



RN 726169-64-8 CAPLUS  
 CN 5-Oxazolidinonecarboxamide, 3-[3-fluoro-4-(3-methyl-2-oxo-3-azabicyclo[3.1.0]hex-6-yl)phenyl]-2-oxo-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

SAEED

10815589

=> LOGOFF

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

27.29

199.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.90

-3.90

STN INTERNATIONAL LOGOFF AT 18:51:10 ON 20 JAN 2007

SAEED